Skip to NavigationSkip to content

News

0
A number of Pharmafile.com’s most popular stories this week are surprisingly unrelated to COVID; researchers in Scotland have made a breakthrough...
0
NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS).
0
Independent pharmaceutical group Servier and RNA activation-focused MiNA Therapeutics have entered a research partnership to identify and develop...
0
Eli Lilly’s neutralising antibody bamlanivimab significantly reduced the risk of contracting symptomatic coronavirus among residents and staff of...

Features

Matt Fellows explores how early and managed access schemes are mutually beneficial to sponsors and patients alike, as well as how to...